Food and Drug Administration v. Alliance for Hippocratic Medicine (2023)
- Docket
- 23-235
- Decided
- 2023-01-01
- Public Good score
- 80 / 100
- Framers' Intent score
- 88 / 100
Summary
Question: <p>1. Do respondents have Article III standing to challenge the Food and Drug Administration’s 2016 and 2021 actions with respect to mifepristone’s approved conditions of use?</p> <p>2. Were the FDA’s 2016 and 2021 approvals of mifepristone arbitrary and capricious?</p> <p>3. Did the district court properly grant preliminary relief?</p> Conclusion: <p>Alliance for Hippocratic Medicine and other plaintiffs lack Article III standing to challenge the Food and Drug Administration’s regulatory actions regarding mifepristone. Justice Brett Kavanaugh authored the unanimous opinion of the Court.</p> <p>The plaintiff doctors and medical associations, none of whom prescribe or use mifepristone, do not allege direct monetary injuries, property injuries, or physical injuries from FDA's actions relaxing the regulation of mifepristone. Rather, they have legal, moral, ideological, and policy concerns about abortion. While these concerns are legitimate, they do not suffice on their own to confer Article III standing to sue in federal court.</p> <p>Given the broad and comprehensive conscience protections guaranteed by federal law, the plaintiffs have not shown that FDA's actions will cause them to suffer any conscience injury. Additionally, the causal link between FDA’s regulatory actions and the alleged monetary and related injuries (e.g., diverting resources, increased risk of liability suits, potentially increasing insurance costs) is too speculative or attenuated to establish standing. Finally, the medical associations have not demonstrated organizational standing. Thus, even if true that no one would be able to challenge FDA’s actions if the plaintiffs cannot, the Court has long rejected this “if not us, who?" argument as a basis for standing.</p> <p>Justice Clarence Thomas authored a concurring opinion reiterating that associational (or organizational) standing is simply another form of third-party standing and that the Court should, in another case, explain just how the Constitution permits associational standing.</p>
Case Brief
Facts
Plaintiffs, comprising doctors and medical associations who do not prescribe or use mifepristone, challenged the FDA's 2016 and 2021 regulatory actions that relaxed restrictions on the drug's use for abortion. They alleged ideological, moral, and policy-based concerns, claiming the FDA's actions would cause them to suffer monetary, property, or conscience injuries. The district court granted preliminary injunctions blocking the FDA's regulations.
Procedural History
Plaintiffs sued in the Fifth Circuit, seeking preliminary relief. The Fifth Circuit initially upheld the FDA's rules but later reversed, granting preliminary injunctions. The Supreme Court granted certiorari to address standing issues before the merits of the FDA's actions.
Issue
Do the plaintiffs have Article III standing to challenge the FDA's regulatory actions regarding mifepristone?
Holding
The plaintiffs lack Article III standing to challenge the FDA's actions because they fail to allege a concrete injury caused by the regulations. Their concerns are ideological and not grounded in a legally protectable interest.
Rule
Article III standing requires a plaintiff to demonstrate a concrete, particularized injury that is actual or imminent, not abstract, ideological, or speculative. Mere moral objections without a tangible injury do not satisfy this requirement. Organizational standing also requires a showing that the injury affects the organization's members in a legally cognizable way.
Reasoning
The plaintiffs allege no direct monetary, property, or physical injury from the FDA's rules—they neither prescribe mifepristone nor face imminent harm. Their claims of diversion of resources and increased litigation risk are too speculative. Federal conscience protections further negate any alleged 'conscience injury.' The Court rejected the 'if not us, who?' argument for standing, emphasizing that standing must be grounded in concrete harm, not generalized grievance.
Significance
This ruling significantly restricts constitutional challenges to government regulations by requiring plaintiffs to demonstrate concrete, particularized harm rather than abstract ideological objections. It reinforces the judiciary's gatekeeping role in preventing courts from adjudicating purely policy disputes under Article III.
Public Good Analysis
GPT: Prevents ideological objections from derailing evidence-based regulatory decisions, stabilizing access to mifepristone as part of essential healthcare. Protects judicial resources from speculative lawsuits while ensuring regulatory challenges require concrete harm, not abstract policy disagreements. | Claude: The Court’s ruling upholds a critical aspect of administrative agency authority and prevents courts from being flooded with cases brought by those lacking demonstrable harm. Protecting the FDA's regulatory process is vital for public health and safety as it ensures medications are properly vetted; denying standing here protects that system. While controversial due to the subject matter, limiting access to federal courts based on concrete injury reinforces a core tenet of justiciability.
Framers' Intent Analysis
GPT: Directly aligns with Federalist No. 80 (Hamilton) emphasizing courts must adjudicate 'actual and substantial' disputes. Upholds original Article III standing requirements as understood by the Framers, rejecting moral or policy concerns as insufficient for judicial review. | Claude: The decision strongly aligns with the framers’ intent regarding limited judicial power and Article III's requirement of 'case or controversy.' James Madison in Federalist No. 80 argued against giving judges roving commissions to address general political grievances, emphasizing that federal courts were designed to resolve concrete disputes, not adjudicate ideological concerns. Strict adherence to standing doctrine reflects this intent by confining the judiciary to actual harms and preventing it from becoming a policy-making body, a concern repeatedly voiced by figures like Thomas Jefferson who feared judicial overreach.